Holen Sie sich die Stockscreener-App
26.30
1.22%
-0.325
Schlusskurs vom Vortag:
$26.63
Offen:
$26.51
24-Stunden-Volumen:
122.63K
Relative Volume:
0.39
Marktkapitalisierung:
$1.53B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-118.12M
KGV:
-11.54
EPS:
-2.2802
Netto-Cashflow:
$-82.63M
1W Leistung:
+7.15%
1M Leistung:
-2.43%
6M Leistung:
+41.76%
1J Leistung:
+69.70%
1-Tages-Spanne:
$26.07
$26.94
1-Wochen-Bereich:
$24.89
$27.93
52-Wochen-Spanne:
$14.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
26.33 | 1.54B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate - Sahm
Risk Check: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS - MarketBeat
Oculis Holding AG renews $100 million at-the-market offering program - investing.com
Why (OCS) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Stifel raises Oculis stock price target to $50 on pipeline progress - investing.com
OCS SEC FilingsOculis Holding 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Oculis Holding AG Equity Warrant attractive for institutional investorsMarket Risk Analysis & Real-Time Price Movement Reports - baoquankhu1.vn
Can Oculis Holding AG continue delivering strong returnsCEO Change & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Aug Analyst Calls: Should I invest in Oculis Holding AG before earningsQuarterly Profit Review & Reliable Volume Spike Alerts - baoquankhu1.vn
Earnings Recap: How does Oculis Holding AG compare to its peersMarket Sentiment Summary & Target Return Focused Picks - baoquankhu1.vn
Oculis (NASDAQ:OCS) Trading Up 9.2%Time to Buy? - MarketBeat
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - The Manila Times
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - GlobeNewswire Inc.
Oculis Holding AG's Privosegtor Receives PRIME Designation from EMA for Treatment of Optic Neuritis, Following FDA Breakthrough Therapy Status - Quiver Quantitative
Oculis drug for sight-threatening optic neuritis wins EMA PRIME - Stock Titan
OCS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bearish Setup: Whats next for Oculis Holding AG stock2026 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Analyst Upgrade: Should you avoid Oculis Holding AG Equity Warrant stock right now2026 Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis - Bitget
EPS Watch: Can Oculis Holding AG Equity Warrant be the next market leader2026 Chart Watch & Safe Entry Momentum Stock Tips - baoquankhu1.vn
OCS PE Ratio & Valuation, Is OCS Overvalued - Intellectia AI
Is Positive Privosegtor Phase 2 Optic Neuritis Data Altering The Investment Case For Oculis Holding (OCS)? - Sahm
Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5% - MarketBeat
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - MarketScreener
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS - MarketBeat
Beyeotech's 2.44M-share stake in Oculis (OCS) equals 4.14% of float - Stock Titan
Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference Summary - Quartr
Understanding Momentum Shifts in (OCS) - news.stocktradersdaily.com
Loss Report: Is Oculis Holding AG Equity Warrant a top pick in the sectorTrade Risk Summary & Technical Pattern Recognition Alerts - baoquankhu1.vn
Growth Recap: Is Oculis Holding AG Equity Warrant stock a value trap2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Decliners: Will Oculis Holding AG benefit from green energy policiesWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Sentiment Review: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Revenue Check: Can Oculis Holding AG Equity Warrant stock double in the next year2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Stop Loss: Whats the MACD signal for Oculis Holding AG2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Oculis Holding AG Presents Promising Phase 2 ACUITY Trial Results for Privosegtor at NANOS 2026 Meeting - quiverquant.com
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - The Manila Times
Experimental eye drug aims to protect vision in optic neuritis - Stock Titan
Oculis board member buys company stock on March 12 and 13 - Stock Titan
Oculis Holding AG (OCS) reports Q4 loss, tops revenue estimates - MSN
Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9% - MarketBeat
Latest OCS NewsOculis to Participate in Jefferies Healthcar... - Stock Titan
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates - MSN
Risk Off: Can Oculis Holding AG beat the S P 500Portfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (OCS) Movement - Stock Traders Daily
Aug Opening: What is the implied volatility of Oculis Holding AG Equity WarrantWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com Nigeria
Three Oculis executives receive 2026 equity awards, filings show - Stock Titan
Biopharma companies hire new legal executives - BioXconomy
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):